U.S. Water Utilities Stock News

On January 15, 2026, Unum Group’s board declared a quarterly dividend of US$0.460 per share, payable on February 20, 2026, to shareholders of record as of January 30, 2026. This reaffirmed dividend, alongside Unum’s broader capital return policies, highlights management’s ongoing emphasis on distributing cash to shareholders. We’ll now examine how Unum’s reaffirmed dividend shapes the company’s existing investment narrative and its capital return profile. Uncover the next big thing with...

In early January 2026, Installed Building Products, Inc. priced a US$500,000,000 offering of 5.625% senior unsecured notes due 2034, intending to redeem its existing 5.75% senior unsecured notes due 2028 and fund general corporate purposes in a private placement to qualified institutional buyers. Around the same time, J.P. Morgan downgraded Installed Building Products to a sell rating, underscoring tensions between the company’s capital structure moves and evolving analyst views on its...

Preformed Line Products recently reported solid third-quarter 2025 results, with strong revenue growth from its core energy and communications markets while managing tariff-related cost pressures and a one-time pension termination charge. The company’s ability to grow operating income and adjusted earnings while continuing to invest in new manufacturing facilities and acquisitions highlights its underlying financial resilience. We’ll now examine how resilient operating performance amid...

Earlier in January 2026, Braze was added to Wells Fargo’s Q1 2026 Tactical Ideas List, while Wells Fargo and Needham both reiterated positive views on the company’s AI-enabled customer engagement platform and commercial progress. Analysts emphasized that Braze’s data-first, AI-focused offerings and flexible pricing initiatives like Flex Credits are strengthening its competitive position and supporting deeper enterprise adoption. We’ll now examine how this renewed analyst enthusiasm around...

Conference appearance puts Ouster in focus Ouster (OUST) is set to present at the 28th Annual Needham Growth Conference on January 15, 2026 in New York, drawing fresh attention to how investors view the lidar stock today. See our latest analysis for Ouster. At a share price of US$26.36, Ouster’s recent pattern has been mixed, with a 30 day share price return of 18.58% alongside a 90 day share price return decline of 13.69%, while its 1 year total shareholder return of 148.68% and 3 year total...

NextNav (NN) is back in focus after its proposal to the FCC for new rules that could support a terrestrial GPS backup system using 5G spectrum, a move tied directly to critical infrastructure discussions. See our latest analysis for NextNav. NextNav's FCC proposal comes after a choppy year in the stock, with a 1-day share price return of 5.16% and a 7-day share price return of 9.64% contrasting with a 30-day share price return of a 6.49% decline. The 1-year total shareholder return of 20.86%...

Why Coca-Cola FEMSA. de (KOF) Is On Investors’ Radar Today Coca-Cola FEMSA. de (KOF) is drawing attention after recent share price moves, with the stock showing a 1 day return of 1.9% and a past 3 months return of 17.9%. See our latest analysis for Coca-Cola FEMSA. de. While the latest 1 day share price return of 1.9% comes after a period of stronger momentum, the 90 day share price return of 17.9% and 1 year total shareholder return of 35.5% point to investors steadily rewarding Coca-Cola...

What the PFAS lawsuit means for Chemours stock A Montana federal judge’s decision to let a wide ranging PFAS class action proceed against Chemours (CC) and other manufacturers has pushed legal risk back into focus for anyone tracking the stock. The lawsuit centers on firefighter turnout gear allegedly containing toxic PFAS chemicals, with claims that manufacturers collectively concealed health risks and failed to offer PFAS free alternatives, despite such options allegedly being feasible. For...

China approval puts focus on ARS Pharmaceuticals’ new market opportunity ARS Pharmaceuticals (SPRY) is back on investor radar after partner Pediatrix Therapeutics received approval from China’s National Medical Products Association for community use of neffy, its intranasal epinephrine spray. This decision makes neffy the first government approved epinephrine product for use outside Chinese hospitals. It creates a fresh addressable market and sets up ARS to collect regulatory milestone...

Microvast Holdings recently strengthened its finance leadership, appointing Rodney Worthen as Chief Financial Officer and hiring former NextDecade executive Eric N. Garcia as Chief Accounting Officer, both effective in early January 2026. These appointments bring a blend of corporate finance, investor relations, and Big Four audit experience that could influence how Microvast manages reporting quality, capital allocation, and future expansion decisions. Next, we’ll examine how bringing in a...

Madison Square Garden Sports (MSGS) is back in focus after reporting Q1 Fiscal 2026 results that beat EPS expectations, while revenue missed forecasts, alongside an amended $425 million revolving credit facility for the Knicks. See our latest analysis for Madison Square Garden Sports. The latest earnings surprise and expanded Knicks credit facility have come alongside a strong price run, with a 30-day share price return of 17.55% and a 1-year total shareholder return of 33.46%. This points to...

In early January 2026, Globus Medical, Inc. issued updated guidance, forecasting fourth-quarter 2025 sales of approximately US$823.2 million and full-year 2025 sales of about US$2.94 billion, while also setting a full-year 2026 revenue range of US$3.18 billion to US$3.22 billion. This guidance points to management’s confidence in underlying demand for its musculoskeletal and enabling technology portfolio, offering investors fresh insight into how scale from recent acquisitions and innovation...

Mineralys Therapeutics (MLYS) is back in focus after reporting third quarter 2025 earnings that surpassed expectations, updating investors on lorundrostat’s path toward a New Drug Application and expanding its clinical program. See our latest analysis for Mineralys Therapeutics. The latest updates on lorundrostat and Q3 2025 results come after a mixed year in the market, with a 1 day share price return of 4.33% to US$32.74, a 90 day share price return decline of 25.86%, and a 1 year total...

On January 8, 2026, Hippocratic AI announced a collaboration with Huron Consulting Group to deploy generative AI healthcare agents that support care navigation, discharge follow-up, chronic condition outreach, and other patient engagement tasks within Huron-led transformation programs across more than 1,000 healthcare organizations. The partnership combines Hippocratic AI's large-scale, safety-focused agent platform with Huron's healthcare consulting expertise, potentially deepening Huron's...

VAALCO Energy (EGY) is drawing attention after reporting full year 2025 production and sales volumes around the midpoint and top of guidance, alongside encouraging drilling results at its Etame complex offshore Gabon. See our latest analysis for VAALCO Energy. The production and sales update lands after a strong run in the share price, with a 7 day share price return of 23.29% and a 30 day share price return of 31.20%. The 5 year total shareholder return of 136.12% points to momentum that has...

American Bitcoin’s new disclosure focus American Bitcoin (ABTC) is drawing fresh attention after highlighting more than 5,098 Bitcoin in reserves and rolling out a Bitcoin Yield Metric aimed at giving investors clearer insight into changes in its holdings. See our latest analysis for American Bitcoin. That renewed focus on its 5,098 Bitcoin reserves and the new Bitcoin Yield Metric comes after a tough period, with American Bitcoin’s share price return declining 67.78% over 90 days and 7.87%...

Origin Bancorp overview and recent performance Origin Bancorp (OBK) has attracted investor attention recently, with the share price around $40.44 and a mix of short term and longer term total returns that give a useful starting point for evaluating the stock. See our latest analysis for Origin Bancorp. While the latest 1-day share price return of 0.10% is relatively muted, the 90-day share price return of 19.40% and 1-year total shareholder return of 17.02% suggest momentum has been building...

Biohaven (BHVN) is back in focus after reporting early clinical experience from its MoDE and TRAP degrader platforms in IgA nephropathy and Graves' disease, along with a fresh pipeline update at a major healthcare conference. See our latest analysis for Biohaven. Biohaven's recent MoDE and TRAP degrader data, along with its high profile conference appearance, comes after a sharp rebound in momentum, with a 7 day share price return of 18.27% and a 30 day share price return of 21.11% from a...

Sila Realty Trust, Inc. recently completed the US$43.1 million acquisition of a fully leased inpatient rehabilitation facility in Oklahoma City, Oklahoma, which has been expanded to 58 beds and is operated under a long-term absolute-net lease with a corporate guaranty. This transaction reinforces Sila Realty Trust’s focus on healthcare real estate anchored by long-duration, necessity-based assets with strong occupancy and limited local competition, aiming to support consistent cash...

In January 2026, 10x Genomics and its partners, including Dana-Farber Cancer Institute, Brigham & Women’s Hospital, the Cancer Research Institute and CareDx, announced a series of collaborations to apply single-cell and spatial technologies across oncology, autoimmune disease, immuno-oncology and transplantation, alongside unaudited 2025 revenue of about US$642.8 million, or US$598.7 million excluding patent litigation settlements. These alliances, together with plans for a CLIA-certified...

Middleby: Recent Performance Snapshot Middleby (MIDD) has been trading quietly, with the share price last closing at US$148.53 and showing mixed returns, including a small move over the past month and a stronger gain across the past 3 months. See our latest analysis for Middleby. While Middleby’s 1-day share price return of 0.21% decline and 7-day share price return of 5.81% decline suggest some recent cooling, the 90-day share price return of 10.44% and 1-year total shareholder return of...

Several firms have recently downgraded Douglas Emmett (DEI), pointing to persistent weakness in occupancy and leasing momentum across its Los Angeles office portfolio, along with lower funds from operations estimates and a slower regional recovery. See our latest analysis for Douglas Emmett. The recent downgrades arrive after a difficult period for investors, with a 1 year total shareholder return of 32.94% decline and a 5 year total shareholder return of 50.07% decline. The latest US$11.12...

Ardent Health (ARDT) is back in focus after a series of securities class action lawsuits tied to disclosures on accounts receivable accounting, higher professional liability reserves, and alleged weaknesses in financial reporting controls. See our latest analysis for Ardent Health. At the latest share price of $8.60, Ardent Health has seen a 41.5% decline in its 90 day share price return and a 39.01% fall in 1 year total shareholder return. Recent lawsuits appear to be keeping pressure on...

What recent performance suggests about Biglari Holdings (BH.A) Recent trading in Biglari Holdings (BH.A) has drawn attention, with the stock showing double digit returns over the past week, month, and past 3 months, prompting investors to reassess what is driving sentiment. See our latest analysis for Biglari Holdings. At a share price of $2,378.72, Biglari Holdings has seen a rapid shift in sentiment, with a 30 day share price return of 35.78% and a 1 year total shareholder return of...